Alkermes plc. (ALKS) Operating Margin
- Operating margin · 12 months: Value 7.03%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 7.03% | Operating income / revenue. Period ending 2026-06-30. $117.26M ÷ $1.67B × 100 ≈ 7.03% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 117.26M USD | Operating Income (Loss) |
| Revenue | 1.67B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 257.49M USD | Cost of Goods and Services Sold |
| Research and development | 391.04M USD | Research and Development Expense |
| Selling, general and administration | 841.19M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $117.26M | $1.67B | $257.49M | $391.04M | $841.19M | 7.03% |
| 2026-03-31 | $191.88M | $1.56B | $208.84M | $355.49M | $794.41M | 12.28% |
| 2025-12-31 | $253.96M | $1.48B | $196.46M | $323.96M | $701.52M | 17.21% |
| 2025-09-30 | $358.54M | $1.52B | $212.36M | $289.10M | $661.32M | 23.57% |
| 2025-06-30 | $374.21M | $1.51B | $223.87M | $267.25M | $639.93M | 24.86% |
| 2025-03-31 | $391.12M | $1.51B | $235.88M | $249.53M | $637.19M | 25.84% |
| 2024-12-31 | $420.64M | $1.56B | $245.33M | $245.33M | $645.24M | 27.00% |
| 2024-09-30 | $312.58M | $1.51B | $253.34M | $261.08M | $668.03M | 20.77% |
| 2024-06-30 | $297.02M | $1.51B | $251.74M | $266.07M | $674.02M | 19.70% |
| 2024-03-31 | $468.40M | $1.73B | $253.52M | $274.65M | $701.67M | 27.14% |
| 2023-12-31 | $414.12M | $1.66B | $253.04M | $270.81M | $689.75M | 24.90% |
| 2023-09-30 | $214.97M | $1.59B | $236.91M | $396.15M | $706.72M | 13.51% |
| 2023-06-30 | $110.48M | $1.46B | $226.02M | $399.44M | $690.05M | 7.56% |
| 2023-03-31 | $-163.17M | $1.12B | $221.12M | $391.53M | $635.17M | -14.56% |
| 2022-12-31 | $-142.26M | $1.11B | $218.11M | $393.84M | $605.75M | -12.80% |
| 2022-09-30 | $-119.30M | $1.13B | $217.83M | $387.63M | $608.61M | -10.54% |
| 2022-06-30 | $-78.32M | $1.17B | $216.76M | $405.61M | $592.05M | -6.67% |
| 2022-03-31 | $-39.44M | $1.20B | $211.53M | $410.21M | $580.86M | -3.28% |
| 2021-12-31 | $-29.29M | $1.17B | $197.39M | $406.53M | $560.98M | -2.50% |
| 2021-09-30 | $-62.40M | $1.13B | $186.63M | $420.26M | $546.35M | -5.53% |
| 2021-06-30 | $-53.41M | $1.10B | $180.20M | $396.83M | $537.79M | -4.85% |
| 2021-03-31 | $-91.49M | $1.04B | $172.13M | $393.58M | $530.62M | -8.76% |
| 2020-12-31 | $-112.43M | $1.04B | $178.32M | $394.59M | $538.83M | -10.82% |
| 2020-09-30 | $-91.63M | $1.17B | $181.88M | $480.64M | $547.50M | -7.82% |
| 2020-06-30 | $-134.59M | $1.16B | $181.06M | $493.33M | $568.55M | -11.59% |
| 2020-03-31 | $-136.85M | $1.19B | $182.24M | $503.54M | $591.60M | -11.46% |
| 2019-12-31 | $-175.48M | $1.17B | $180.38M | $512.83M | $599.45M | -14.99% |
| 2019-09-30 | $-165.53M | $1.07B | $183.02M | $423.65M | $586.22M | -15.41% |
| 2019-06-30 | $-149.06M | $1.07B | $180.11M | $417.24M | $566.30M | -13.96% |
| 2019-03-31 | $-113.24M | $1.09B | $177.31M | $419.63M | $549.48M | -10.37% |
| 2018-12-31 | $-99.13M | $1.09B | $176.42M | $425.41M | $526.41M | -9.06% |
| 2018-09-30 | $-93.31M | $1.05B | (m) | $420.92M | $496.08M | -8.85% |
| 2018-06-30 | $-94.51M | $1.02B | (m) | $424.07M | $466.93M | -9.24% |
| 2018-03-31 | $-138.92M | $936.75M | (m) | $416.40M | $437.63M | -14.83% |
| 2017-12-31 | $-147.90M | $903.37M | (m) | $412.89M | $421.58M | -16.37% |
| 2017-09-30 | $-177.27M | $841.52M | (m) | $398.02M | $407.83M | -21.07% |
| 2017-06-30 | $-200.04M | $804.37M | (m) | $393.06M | $399.34M | -24.87% |
| 2017-03-31 | $-202.65M | $780.70M | (m) | $390.91M | $386.51M | -25.96% |
| 2016-12-31 | $-208.66M | $745.69M | (m) | $387.15M | $374.13M | -27.98% |
| 2016-09-30 | $-252.19M | $695.28M | (m) | $391.21M | $364.46M | -36.27% |
| 2016-06-30 | $-268.47M | $667.69M | (m) | $384.32M | $362.81M | -40.21% |
| 2016-03-31 | $-273.88M | $623.89M | (m) | $375.20M | $338.23M | -43.90% |
| 2015-12-31 | $-224.30M | $628.34M | (m) | $344.40M | $311.56M | -35.70% |
| 2015-09-30 | $-172.93M | $640.40M | (m) | $325.15M | $278.89M | -27.00% |
| 2015-06-30 | $-128.25M | $647.74M | (m) | $310.86M | $241.28M | -19.80% |
| 2015-03-31 | $-98.56M | $649.79M | (m) | $290.18M | $220.41M | -15.17% |
| 2014-12-31 | $-87.14M | $618.79M | (m) | $272.04M | $199.91M | -14.08% |
| 2014-09-30 | $-65.61M | $598.11M | (m) | $246.33M | $189.27M | -10.97% |
| 2014-06-30 | $-36.75M | $577.92M | (m) | $214.01M | $176.84M | -6.36% |
| 2014-03-31 | $-399.00K | $563.12M | (m) | $180.26M | $159.11M | -0.07% |
| 2013-12-31 | $34.48M | $596.33M | (m) | $163.93M | $151.24M | 5.78% |
| 2013-09-30 | $53.90M | $577.76M | (m) | $146.53M | $136.93M | 9.33% |
| 2013-06-30 | $63.20M | $561.94M | (m) | $135.67M | $128.91M | 11.25% |
| 2013-03-31 | $81.81M | $575.55M | (m) | $140.01M | $125.76M | 14.21% |
| 2012-12-31 | $5.16M | $542.60M | (m) | $149.40M | $125.51M | 0.95% |
| 2012-09-30 | $-25.07M | $532.33M | (m) | $158.58M | $131.11M | -4.71% |
| 2012-06-30 | $-42.25M | $480.33M | (m) | $151.65M | $135.92M | -8.80% |
| 2012-03-31 | $-88.28M | $389.98M | (m) | $141.89M | $137.63M | -22.64% |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $-45.63M | $186.64M | (m) | $97.24M | $82.85M | -24.45% |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $-43.03M | $178.28M | (m) | $95.36M | $76.51M | -24.14% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |